Quote:
Originally Posted by T3rminator
You guys at least have contingency in place with 5 others, so 6 all up. And your deals cover your population 6 times over according to the article below. I would have initially said this smells a bit greedy, hoarding all the vacs, but its now looking like a good risk management move as not all "deals" will be met.
https://www.smh.com.au/world/oceania...06-p57gtz.html
"New Zealand has purchase agreements for 30.3 million doses of four different COVID-19 vaccines: Pfizer, Novavax, AstraZeneca vaccine, and the Janssen/Johnson & Johnson.
That is enough to cover the population of almost 5 million people more than six times over." |
We have agreements for 170m with the latest announcement but a less diverse range. So in a similar boat dose wise vs population.
The biggest difference is we are one of few countries in the world with local manufacturing though how much that is worth given the last 24hrs is yet to be seen.
I personally still think it is well worthwhile continuing with the local manufacturing in the meantime.
CSL could potentially switch to a different vaccine but there really isn't much point in doing that unless the trials are better than AZ and there has been wider vaccinations with another candidate given where we are at now.